• Satellos Bioscience's net loss widened 92% year-over-year to USD 11.17 million for the three months ended September 30, 2026.
• Research and development expenses more than doubled to USD 9 million, while general and administrative costs rose 36% to USD 2.68 million.
• At September 30, cash and cash equivalents totaled USD 6.18 million, while short-term investments reached USD 46.84 million.
• A September funding agreement with FSHD Canada Foundation provides up to USD 4.89 million in milestone-based support for eligible research and development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Satellos Bioscience Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-007371), on November 12, 2026, and is solely responsible for the information contained therein.